Christopher A. Alabi

This paper develops programmable protein degraders (uAbs) that selectively knock down pathogenic β-catenin in vitro and in vivo, reducing tumor cell survival and proliferation.

This paper develops lipid nanoparticles for intracellular antibody delivery, showing efficacy in inhibiting cytosolic targets in cancer and disease models.

This study designs and tests a stabilized full-length measles fusion protein antigen that induces strong neutralizing antibodies and protects against viral challenge in a cotton rat model.

This paper develops multifunctional reagents for nanoscale imaging of glycans using expansion microscopy, validated in C. elegans and mammalian cells.

The paper identifies a single-subunit oligosaccharyltransferase from Desulfovibrio marinus that enables glycosylation of full-length IgG antibodies in E. coli.

This study develops a method to deliver proteins into cells using ionizable lipid nanoparticles by modifying protein surfaces with an anionic cloak, demonstrating efficacy in cancer cell killing and signaling inhibition.

This study uses lipid nanoparticles to deliver peptide-based degraders, enabling targeted protein degradation in cancer cells and demonstrating reduced target levels in mice.